|
|
| Line 1: |
Line 1: |
| - | * [[Pathway:WP4156]] - Chapter 1 "Disorders of Phenylalanine and Tetrahydrobiopterin (BH4) Metabolism"
| + | {| |
| - | * [[Pathway:WP4506]] - Chapter 2 "Tyrosine Metabolism"
| + | | |
| - | * [[Pathway:WP4292]] - Chapter 3 "Sulphur Amino Acids"
| + | {{ #pathwayOfTheDay: {{LOCALDAYNAME}} {{LOCALDAY}} {{LOCALMONTHNAME}} {{LOCALYEAR}} | Portal:Disease/BlauBookPathways}} |
| | + | |align="right"|[[Image:Blau_cover.jpg|170px]] |
| | + | |} |
| | + | <p>View all [[Portal:Disease/BlauBookPathways|Pathways]] digitized from [https://tools.wmflabs.org/scholia/work/Q54006412 Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases] by Blau ''et al.''</p> |
| | + | |
| | | | |
| - | * [[Pathway:WP4259]] - Chapter 10 "Disorders of Folate Metabolism and Transport"
| + | <b>How to add a pathway to the portal</b> |
| - | * [[Pathway:WP4288]] - Chapter 10 "MTHFR deficiency (additional pathway)"
| + | |
| | | | |
| - | {| style="margin: 10px"
| + | The list of Featured Pathways is not static and can be updated at any time. If you know of a pathway that should be added, please [mailto:denise.slenter@maastrichtuniversity contact Denise Slenter]. |
| - | |width=100px; cell padding=50px|{{#pwImage:Pathway:WP4156|250px||Disorders of Phenylalanine and Tetrahydrobiopterin (BH4) Metabolism}}
| + | |
| - | |width=100px|{{#pwImage:Pathway:WP4506|250px||Tyrosine Metabolism}}
| + | |
| - | |width=100px|{{#pwImage:Pathway:WP4292|250px||Sulphur Amino Acids}}
| + | |
| - | |width=100px|{{#pwImage:Pathway:WP4259|250px||Disorders of Folate Metabolism and Transport}}
| + | |
| - | |width=100px|{{#pwImage:Pathway:WP4288|250px||MTHFR deficiency (additonal pathway)}}
| + | |
| - | |}
| + | |
| - | | + | |
| - | * [[Pathway:WP4228]] - Chapter 11 "Vitamine B6-Dependent and Responsive Disorders"
| + | |
| - | | + | |
| - | * [[Pathway:WP4507]] - Chapter 12 "Molybdenum (Moco) cofactor biosynthesis"
| + | |
| - | * [[Pathway:WP4504]] - Chapter 12 "Cysteine and Methionine catabolism"
| + | |
| - | | + | |
| - | * [[Pathway:WP4271]] - Chapter 13 "Vitamin B12 Disorders"
| + | |
| - | * [[Pathway:WP4297]] - Chapter 15 "Thiamine Disorders"
| + | |
| - | | + | |
| - | {| style="margin: 10px"
| + | |
| - | |width=100px; cell padding=50px|{{#pwImage:Pathway:WP4228|250px||Vitamine B6-Dependent and Responsive Disorders}}
| + | |
| - | |width=100px|{{#pwImage:Pathway:WP4507|250px||Molybdenum (Moco) cofactor biosynthesis}}
| + | |
| - | |width=100px|{{#pwImage:Pathway:WP4504|250px||Cysteine and Methionine catabolism}}
| + | |
| - | |width=100px|{{#pwImage:Pathway:WP4271|250px||Vitamin B12 Disorders}}
| + | |
| - | |width=100px|{{#pwImage:Pathway:WP4297|250px||Thiamine Disorders}}
| + | |
| - | |}
| + | |
| - | | + | |
| - | * [[Pathway:WP4236]] - Chapter 20 "Disorders of the Krebs Cycle"
| + | |
| - | * [[Pathway:WP4153]] - Chapter 25 "Lysosomal Storage Disorders Including Neuronal Ceroid Lipofuscinoses (Sphingolipid degradation)"
| + | |
| - | * [[Pathway:WP4220]] - Chapter 31 "Neurotransmitter Disorders"
| + | |
| - | | + | |
| - | * [[Pathway:WP4224]] - Chapter 41 "Purine Disorders"
| + | |
| - | * [[Pathway:WP4225]] - Chapter 41 "Pyrimidine Disorders"
| + | |
| - | | + | |
| - | {| style="margin: 10px"
| + | |
| - | |width=100px; cell padding=50px|{{#pwImage:Pathway:WP4236|250px||Disorders of the Krebs Cycle}}
| + | |
| - | |width=100px|{{#pwImage:Pathway:WP4153|250px||Lysosomal Storage Disorders Including Neuronal Ceroid Lipofuscinoses (Sphingolipid degradation)}}
| + | |
| - | |width=100px|{{#pwImage:Pathway:WP4220|250px||Neurotransmitter Disorders}}
| + | |
| - | |width=100px|{{#pwImage:Pathway:WP4224|250px||Purine Disorders}}
| + | |
| - | |width=100px|{{#pwImage:Pathway:WP4225|250px||Pyrimidine Disorders}}
| + | |
| - | |}
| + | |
| - | | + | |
| - | | + | |
| - | Pathways with kinetics data [coming soon!]. | + | |
| - | * [[Pathway:WP4519]] - Chapter 8 "Cerebral Organic Acidurias, including diseases"
| + | |
| - | * [[Pathway:WP4521]] - Chapter 30 "Glycosylation and related congenital defects."
| + | |
| - | * [[Pathway:WP4523]] - Chapter 37 "Classical pathway of steroidogenesis, including diseases"
| + | |
| - | * [[Pathway:WP4524]] - Chapter 37 "The alternative pathway of fetal androgen synthesis, including diseases"
| + | |
| - | * [[Pathway:WP4518]] - Chapter 42 "Gamma-Glutamyl Cycle for the biosynthesis and degradation of glutathione, including diseases"
| + | |
| - | * [[Pathway:WP4522]] - Chapter 43 "Metabolic pathway of LDL, HDL and TG, including diseases"
| + | |
| - | | + | |
| - | {| style="margin: 10px"
| + | |
| - | |width=60px; cell padding=50px|{{#pwImage:Pathway:WP4519|250px||Cerebral Organic Acidurias, including diseases}}
| + | |
| - | |width=60px|{{#pwImage:Pathway:WP4521|230px||Glycosylation and related congenital defects.}}
| + | |
| - | |width=60px|{{#pwImage:Pathway:WP4523|230px||Classical pathway of steroidogenesis, including diseases}}
| + | |
| - | |width=60px|{{#pwImage:Pathway:WP4524|230px||The alternative pathway of fetal androgen synthesis, including diseases}}
| + | |
| - | |width=60px|{{#pwImage:Pathway:WP4518|230px||Gamma-Glutamyl Cycle for the biosynthesis and degradation of glutathione, including diseases}}
| + | |
| - | |width=60px|{{#pwImage:Pathway:WP4522|230px||Metabolic pathway of LDL, HDL and TG, including diseases}}
| + | |
| - | |}
| + | |
The list of Featured Pathways is not static and can be updated at any time. If you know of a pathway that should be added, please contact Denise Slenter.
